Print Page     Close Window     

SEC Filings

10-K
SERES THERAPEUTICS, INC. filed this Form 10-K on 03/06/2019
Entire Document
 

SERES THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)

 

 

 

Year Ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration revenue - related party

 

$

26,917

 

 

$

32,100

 

 

$

21,766

 

Grant revenue

 

 

1,350

 

 

 

 

 

 

 

Total revenue

 

 

28,267

 

 

 

32,100

 

 

 

21,766

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

$

95,955

 

 

 

89,455

 

 

 

81,989

 

General and administrative expenses

 

 

32,596

 

 

 

34,040

 

 

 

32,616

 

Total operating expenses

 

 

128,551

 

 

 

123,495

 

 

 

114,605

 

Loss from operations

 

 

(100,284

)

 

 

(91,395

)

 

 

(92,839

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

1,172

 

 

 

1,590

 

 

 

1,260

 

Other income

 

 

170

 

 

 

425

 

 

 

 

Total other income (expense), net

 

 

1,342

 

 

 

2,015

 

 

 

1,260

 

Net loss

 

$

(98,942

)

 

 

(89,380

)

 

 

(91,579

)

Net loss per share attributable to common stockholders, basic and diluted

 

$

(2.43

)

 

$

(2.21

)

 

$

(2.30

)

Weighted average common shares outstanding, basic and diluted

 

 

40,743,492

 

 

 

40,449,410

 

 

 

39,846,928

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on investments, net of tax of $0

 

 

146

 

 

 

3

 

 

 

(179

)

Total other comprehensive income (loss)

 

 

146

 

 

 

3

 

 

 

(179

)

Comprehensive loss

 

$

(98,796

)

 

$

(89,377

)

 

$

(91,758

)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

 

F-4



© Seres Therapeutics. All Rights Reserved.